Cargando…

A prediction model for major adverse cardiovascular events (MACE) in patients with coronavirus disease 2019 (COVID-19)

BACKGROUND: Emerging evidence shows that cardiovascular injuries and events in coronavirus disease 2019 (COVID-19) should be considered. The current study was conducted to develop an early prediction model for major adverse cardiovascular events (MACE) during hospitalizations of COVID-19 patients. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Dong, Yang, Huan, Yu, He, Wang, Ting, Chen, Zhu, Yao, Rong, Liang, Zongan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9466355/ https://www.ncbi.nlm.nih.gov/pubmed/36096832 http://dx.doi.org/10.1186/s12890-022-02143-3

Ejemplares similares

Current Progress of Studies of Coronary CT for Risk Prediction of Major Adverse Cardiovascular Event (MACE)
por: Zheng, Jianan, et al.
Publicado: (2021)

MACE in the Race: A Canadian Perspective on Major Adverse Cardiac Events (MACE) During Running
por: Abrahim, Mohammed
Publicado: (2022)

A novel risk score to predict cardiovascular complications in patients with coronavirus disease 2019 (COVID‐19): A retrospective, multicenter, observational study
por: Huang, Dong, et al.
Publicado: (2020)

Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE)
por: Chen, Dongqing, et al.
Publicado: (2023)

Diagnostic Value of Hematological and Biochemical Parameters Combinations for Predicting Coronavirus Disease 2019 (COVID-19) in Suspected Patients
por: Huang, Dong, et al.
Publicado: (2021)

Blood Urea Nitrogen to Serum Albumin Ratio (BAR) Predicts Critical Illness in Patients with Coronavirus Disease 2019 (COVID-19)
por: Huang, Dong, et al.
Publicado: (2021)

Major adverse cardiovascular event (MACE) after percutaneous coronary intervention in one-year follow-up study
por: Farshidi, Hossein, et al.
Publicado: (2018)

Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights
por: Marsal, Josep Ramon, et al.
Publicado: (2022)

Risk prediction model for major adverse cardiovascular events (MACE) during hospitalization in patients with coronary heart disease based on myocardial energy metabolic substrate
por: Na, Li, et al.
Publicado: (2023)

Major Adverse Cardiovascular Events (MACE) in COVID-19 Infection and the Role of Cardiac Biomarkers: A Systematic Literature Review
por: Mahendran, S., et al.
Publicado: (2021)

Association of Race and Major Adverse Cardiac Events (MACE): The Atherosclerosis Risk in Communities (ARIC) Cohort
por: Franey, Ericha G, et al.
Publicado: (2020)

Reduction of Major Adverse Cardiovascular Events (MACE) after Bariatric Surgery in Patients with Obesity and Cardiovascular Diseases: A Systematic Review and Meta-Analysis
por: Sutanto, Andryanto, et al.
Publicado: (2021)

Six-month adherence to Statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes
por: Xie, Gaoqiang, et al.
Publicado: (2017)

331 A Machine Learning-based Pharmacogenomic Association Study of Major Adverse Cardiovascular Events (MACEs) in Caribbean Hispanic Patients on Clopidogrel
por: Arroyo, Luis A. Rosario, et al.
Publicado: (2022)

4423 Impact of Gender on High On-Treatment Platelet Reactivity (HPR) and Major Adverse Cardiovascular Events (MACEs) in Caribbean Hispanic patients using Clopidogrel
por: Nunez Medina, Hector Jose, et al.
Publicado: (2020)

Retrospective Study of Appropriate Primary Prevention in Postmenopausal Women Presenting with a Major Adverse Cardiovascular Endpoint (MACE)
por: Cieri-Hutcherson, Nicole E., et al.
Publicado: (2022)

Pericoronary fat inflammation and Major Adverse Cardiac Events (MACE) in prediabetic patients with acute myocardial infarction: effects of metformin
por: Sardu, Celestino, et al.
Publicado: (2019)

The Relationship Between Cardiac Troponin in People Hospitalised for Exacerbation of COPD and Major Adverse Cardiac Events (MACE) and COPD Readmissions
por: Kallis, Constantinos, et al.
Publicado: (2023)

Major adverse cardiovascular events (MACE) in patients with severe COVID-19 registered in the ISARIC WHO clinical characterization protocol: A prospective, multinational, observational study
por: Reyes, Luis Felipe, et al.
Publicado: (2023)

Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Risk of a major adverse cardiovascular event (MACE) following first-ever hospitalisation for acute gout: a Western Australian population-level linked data study.
por: Lopez, Derrick, et al.
Publicado: (2022)

O054 What Measure of CPAP Treatment is most closely Associated with Reduced Risk of Future Major Cardiovascular Events (MACE)?
por: Reynor, A, et al.
Publicado: (2023)

Association between high sensitivity C-reactive protein (hs-CRP) levels and the risk of major adverse cardiovascular events (MACE) and/or microembolic signals after carotid angioplasty and stenting
por: Foroughinia, Farzaneh, et al.
Publicado: (2019)

Additional Value of Non-contrast Chest CT in the Prediction of Adverse Cardiovascular Events in Patients With Novel Coronavirus Disease 2019 (COVID-19)
por: Li, Shuang, et al.
Publicado: (2021)

Rhinitis induced to mace
por: Sanchez Moreno, Gema Vanesa, et al.
Publicado: (2011)

Major cardiovascular events in patients with Coronavirus Disease 2019: Experience of a cardiovascular department of Northern Italy()
por: Bellosta, Raffaello, et al.
Publicado: (2021)

Effects of opium use on one-year major adverse cardiovascular events (MACE) in the patients with ST-segment elevation MI undergoing primary PCI: a propensity score matched - machine learning based study
por: Jenab, Yaser, et al.
Publicado: (2023)

The association between 24-h blood pressure variability and major adverse cardiac events (MACE) in hospitalized patients with acute myocardial infarction: a retrospective cohort study
por: Harefa, et al.
Publicado: (2021)

Evidential MACE prediction of acute coronary syndrome using electronic health records
por: Hu, Danqing, et al.
Publicado: (2019)

Genetic information improves the prediction of major adverse cardiovascular events in the GENEMACOR population
por: Mendonça, Maria Isabel, et al.
Publicado: (2021)

Cardiac rehabilitation performance predicts 1‐year major adverse cardiovascular events
por: Naami, Robert, et al.
Publicado: (2022)

Decrease in Reported Rates of Cardiovascular Device-Related Adverse Events During the Coronavirus Disease 2019 Pandemic
por: Zhou, Elsa S., et al.
Publicado: (2022)

Utilizing dynamic treatment information for MACE prediction of acute coronary syndrome
por: Duan, Huilong, et al.
Publicado: (2019)

Utilizing Chinese Admission Records for MACE Prediction of Acute Coronary Syndrome
por: Hu, Danqing, et al.
Publicado: (2016)

Development and validation a nomogram for predicting the risk of severe COVID-19: A multi-center study in Sichuan, China
por: Zhou, Yiwu, et al.
Publicado: (2020)

Exploiting an early warning Nomogram for predicting the risk of ICU admission in patients with COVID-19: a multi-center study in China
por: Zhou, Yiwu, et al.
Publicado: (2020)

Comparison of cardiovascular biomarker expression in extracellular vesicles, plasma and carotid plaque for the prediction of MACE in CEA patients
por: Verwer, Maarten C., et al.
Publicado: (2023)

Potential adverse effects of coronavirus disease 2019 on the cardiovascular system
por: Bing-Yin, Wang, et al.
Publicado: (2021)

CHADS(2) Scores in the Prediction of Major Adverse Cardiovascular Events in Patients with Cushing's Syndrome
por: Wang, Yuh-Feng, et al.
Publicado: (2014)

Major adverse events and atrial tachycardia in Ebstein’s anomaly predicted by cardiovascular magnetic resonance
por: Rydman, Riikka, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_486vmmdkhhiuv97hokh01ok338